Silence Therapeutics PLC (SLN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.23B
Last updated: Nov 17, 2026 at 4:15 PM ET
Silence Therapeutics PLC (SLN) Statistics
Silence Therapeutics (SLN) has a market cap of $1.23B. Its share count is up 250.60% from a year earlier.
Total Valuation
| Market Cap | $1.23B |
|---|---|
| Latest price (Nov 17, 2026) | $19.80 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 882.5x and 5.1x. Its year-end P/S ranged from 2.0x to 104.2x from 2020 to 2025.
| P/S Ratio | 882.5x |
|---|---|
| P/B Ratio | 5.1x |
Price Statistics
The stock is up 189.90% over 52 weeks and trades 32.98% above its 50-day average.
| Beta (1Y) | 1.44 |
|---|---|
| 52-Week Change | +189.90% |
| 1-Month Change | +1.12% |
| 3-Month Change | +45.48% |
| 6-Month Change | +243.15% |
| 5-Year Change | -10.19% |
| Total Return (1Y) | +189.90% |
| Total Return (3Y CAGR) | +29.57% |
| Total Return (5Y CAGR) | -4.37% |
| Return vs SPY (1Y) | +181.77% |
| Max Drawdown (1Y) | -43.75% |
| Max Drawdown (3Y) | -91.70% |
| Sharpe Ratio (1Y) | 0.95 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $14.89 |
| 200-Day Average | $9.93 |
| 52-Week Range | $4.19 to $19.86 |
| RSI (14 Days) | 77.7 |
| Average Volume (20 Days) | 1.49M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 23.94x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 23.94x |
|---|---|
| Quick Ratio | 23.94x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -22.85% |
|---|---|
| Receivables Turnover | 0.11x |
Scores
SLN has an Altman Z-Score of 7.21, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 7.21 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SLN
What is SLN's market cap?
Silence Therapeutics has a market cap of $1.23B.
How many shares of SLN are outstanding?
Silence Therapeutics has 55.20M shares outstanding. The count is up 250.60% from a year earlier.
Does SLN pay a dividend?
No. Silence Therapeutics does not pay a dividend.
SLN pages: Overview, Charting, Statistics, Valuation, Competitors